Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites with troubled regulatory histories. | From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites with troubled regulatory histories.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

In an initiative to increase the efficiency of drug manufacturing in the United States, the FDA has

After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing…

Following an inspection earlier this year that yielded a Form 483, Indian generics juggernaut Alembic Pharmaceuticals has…

Scholar Rock has shed Novo Nordisk’s troubled Cata | Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a…

This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s…

Amid multiple efforts to rein in steep drug costs in the U.S., Colorado has received the all-clear to take matters into its own…